In late 2024, the prediction marketplace Kalshi started letting users bet on whether an experimental cancer drug named AOH1996 would advance to a phase 2 trial before the end of 2025. When no announcement arrived by the deadline, the bet resolved as a loss, even though studies of the drug, named after Anna Olivia Healey, a child who died of cancer, remained ongoing. By July 2026, Kalshi announced a formal pilot program allowing bets on clinical trial outcomes alongside platforms like Polymarket that already host bets on regulatory decisions. What traders treat as a novel forecasting tool has triggered fierce pushback from physicians, researchers, and clinical trial leaders across the country. For patients volunteering in human studies and policymakers overseeing medical research, turning unfinished science into a betting market raises urgent questions about confidentiality, ethics, and scientific validity.
At the heart of medical research is a strict commitment to confidentiality and unbiased observation. Clinical trials rely on randomization, blinding, and tight control over nonpublic data so researchers can determine whether a treatment genuinely works. Regulators and physicians have warned that attaching financial wagers to active studies threatens this very foundation of clinical research. While Kalshi argues that stock markets already create financial incentives without ruining science, it’s not the same. Even if principal investigators rarely place direct bets, financial incentives can tempt insiders or peripheral staff to leak confidential clues, while forcing research sites, especially private clinics with lighter oversight, to impose costly conflict-of-interest checks down to package couriers. Putting a financial incentive at the level of online gambling platforms could seriously compromise the integrity of the trial by encouraging patients and trial participants to try to monetize the information. If the bet can be won by reporting positive results, patients or care givers, for example, may have the incentive to change patient reported outcomes, hide adverse events, or compromise the trial in other ways.
Public betting odds can quietly reshape the behavior of patients enrolled in ongoing studies. Clinical trials depend on volunteers giving informed consent and following study protocols from initial treatment through final follow-up visits. Even after enrollment closes, participants can see live market odds rising or falling on their screens. Clinical operations experts warn that patients watching odds sink may skip visits or drop out entirely, while those seeing odds surge might seek the therapy outside the trial. Those subtle behavioral shifts introduce attrition bias and dilute treatment data, making it harder for a study to produce a clear, reliable answer.
For consumers and policymakers, the clash exposes a growing regulatory blind spot between financial platforms and human research protections. Prediction markets operate under federal commodities oversight rather than the clinical and securities frameworks designed to safeguard patients and biomedical integrity. In the absence of clear statutory limits, research sponsors and clinical sites face heavier administrative burdens that could slow drug development and drive up the cost of new medicines. Health policy experts argue that the risks to vulnerable patient populations and scientific trust currently outweigh any perceived forecasting benefit.
Safeguarding medical progress requires keeping clinical trials focused on patient welfare and rigorous truth-seeking rather than speculative profit. Policymakers have a clear responsibility to examine whether existing commodities rules adequately protect active human experiments or whether Congress should prohibit wagering on ongoing trials altogether. At the same time, regulators and research institutions must reinforce confidentiality controls and transparent communication so trial participants are never treated like athletes on a scoreboard. When people volunteer their bodies and time to test experimental therapies, they deserve confidence that science, not gambling odds, governs every step of the process. Protecting the integrity of clinical trials today ensures that tomorrow’s treatments rest on trustworthy evidence rather than market speculation.